Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
Plus Therapeutics (PSTV) will present Phase 1 interim data for its ReSPECT-LM trial at the 2024 San Antonio Breast Cancer Symposium. The presentation will focus on Rhenium (186Re) Obisbemeda treatment for leptomeningeal metastases (LM) in breast cancer patients.
The presentation, led by Dr. Andrew Brenner from the University of Texas Health Science Center, is scheduled for December 13, 2024. LM is a rare but serious cancer complication affecting the cerebrospinal fluid and leptomeninges, with breast cancer being the most common primary cancer leading to LM. The condition affects 3-5% of breast cancer patients and has a poor prognosis, with 1-year and 2-year survival rates of only 7% and 3%, respectively. Currently, there are no FDA-approved therapies specifically for LM.
Plus Therapeutics (PSTV) presenterà dati intermedi della Fase 1 del suo trial ReSPECT-LM al Simposio sul Cancro al Seno di San Antonio 2024. La presentazione si concentrerà sul trattamento con Rhenio (186Re) Obisbemeda per le metastasi leptomeningeali (LM) nei pazienti affetti da cancro al seno.
La presentazione, guidata dal Dr. Andrew Brenner dell'Università della Texas Health Science Center, è programmata per il 13 dicembre 2024. LM è una complicanza cancerosa rara ma grave che colpisce il liquido cerebrospinale e le leptomeningi, con il cancro al seno che è il tumore primario più comune che porta a LM. La condizione colpisce il 3-5% dei pazienti con cancro al seno e ha una cattiva prognosi, con tassi di sopravvivenza a 1 anno e 2 anni pari solo al 7% e al 3%, rispettivamente. Attualmente, non ci sono terapie approvate dalla FDA specificamente per LM.
Plus Therapeutics (PSTV) presentará datos interinos de la Fase 1 de su ensayo ReSPECT-LM en el Simposio de Cáncer de Mama de San Antonio 2024. La presentación se centrará en el tratamiento con Rhenio (186Re) Obisbemeda para metástasis leptomeníngeas (LM) en pacientes con cáncer de mama.
La presentación, liderada por el Dr. Andrew Brenner de la Universidad de Texas Health Science Center, está programada para el 13 de diciembre de 2024. Las LM son una complicación cancerosa rara pero grave que afecta el líquido cefalorraquídeo y las leptomeninges, siendo el cáncer de mama el cáncer primario más común que conduce a LM. Esta condición afecta al 3-5% de los pacientes con cáncer de mama y tiene un pronóstico desfavorable, con tasas de supervivencia del 1 y 2 años de solo el 7% y el 3%, respectivamente. Actualmente, no hay terapias aprobadas por la FDA específicamente para LM.
플러스 테라퓨틱스 (PSTV)는 2024년 샌안토니오 유방암 심포지엄에서 ReSPECT-LM 시험의 1상 중간 데이터를 발표할 예정입니다. 이 발표는 유방암 환자에서 지율막 전이 (LM)에 대한 렌튬(186Re) 오비스베메다 치료에 초점을 맞출 것입니다.
이 발표는 텍사스 의과대학의 Andrew Brenner 박사가 진행하며, 2024년 12월 13일로 예정되어 있습니다. LM은 뇌척수액과 지율막에 영향을 미치는 드물지만 심각한 암 합병증으로, 유방암이 LM으로 이어지는 가장 흔한 원발암입니다. 이 상태는 유방암 환자의 3~5%에 영향을 미치며 예후가 좋지 않아, 1년 및 2년 생존율이 각각 7%와 3%에 불과합니다. 현재 LM에 대해 FDA에서 승인한 치료법은 없습니다.
Plus Therapeutics (PSTV) présentera des données intermédiaires de la Phase 1 de son essai ReSPECT-LM lors du Symposium sur le cancer du sein de San Antonio 2024. La présentation se concentrera sur le traitement par Rhénium (186Re) Obisbemeda pour des métastases leptomeningeales (LM) chez des patientes atteintes de cancer du sein.
La présentation, dirigée par le Dr Andrew Brenner de l'Université du Texas Health Science Center, est prévue pour le 13 décembre 2024. Les LM sont une complication rare mais grave du cancer, affectant le liquide céphalorachidien et les leptomeninges, le cancer du sein étant le cancer primaire le plus courant menant à LM. Cette condition touche 3 à 5 % des patientes atteintes de cancer du sein et a un mauvais pronostic, avec des taux de survie à 1 an et 2 ans de seulement 7 % et 3 %, respectivement. Actuellement, il n'existe aucune thérapie approuvée par la FDA spécifiquement pour les LM.
Plus Therapeutics (PSTV) wird interimistische Phase-1-Daten für seine ReSPECT-LM-Studie auf dem San Antonio Breast Cancer Symposium 2024 präsentieren. Die Präsentation wird sich auf die Behandlung mit Rhenium (186Re) Obisbemeda für leptomeningeale Metastasen (LM) bei Brustkrebspatienten konzentrieren.
Die Präsentation wird von Dr. Andrew Brenner vom University of Texas Health Science Center geleitet und ist für den 13. Dezember 2024 geplant. LM ist eine seltene, aber schwerwiegende Komplikation von Krebs, die die Rückenmarksflüssigkeit und die Leptomeningen betrifft, wobei Brustkrebs die häufigste Primärerkrankung ist, die zu LM führt. Der Zustand betrifft 3-5 % der Brustkrebspatienten und hat eine schlechte Prognose, mit einer 1- und 2-Jahres-Überlebensrate von nur 7 % bzw. 3 %. Derzeit gibt es keine von der FDA zugelassenen Therapien speziell für LM.
- Addressing an unmet medical need with no current FDA-approved therapies
- Targeting a growing market as LM incidence is increasing
- None.
Company to present ReSPECT-LM Phase 1 trial data on Rhenium (186Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients
AUSTIN, Texas, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will present data at the 2024 San Antonio Breast Cancer Symposium, December 10-13, 2024 in San Antonio, Texas.
Presentation:
| Title | Rhenium (186Re) obisbemeda (rhenium nanoliposome,186RNL) for the treatment of leptomeningeal metastases (LM): Update on Phase 1 dose escalation (Abstract Number: SESS-2271, Presentation ID: PS14-01) | |
| Presenter | Andrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, Science Center at San Antonio | |
| Date/Time | Friday, 13 December 2024 7:30-8:30 a.m. CST | |
| Location | Stars at Night Ballroom 3-4, Henry B. Gonzalez Convention Center |
About Leptomeningeal Metastases (LM)
LM is a rare complication of cancer in which the primary cancer spreads to the cerebrospinal fluid (CSF) and leptomeninges surrounding the brain and spinal cord. All malignancies originating from solid tumors, primary brain tumors, or hematological malignancies have this LM complication potential with breast cancer as the most common cancer linked to LM, with 3
About Rhenium (186Re) obisbemeda
Rhenium (186Re) obisbemeda is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. Rhenium (186Re) obisbemeda has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. Rhenium (186Re) obisbemeda is being evaluated for the treatment of recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Cautionary Statement Regarding Forward-Looking Statements
This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential promise of rhenium (186Re) obisbemeda including the ability of rhenium (186Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses, and the potential commercialization of the Company’s products.
The forward-looking statements included in this press release could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash to fund its operations in the near term and long term, on terms acceptable to us or at all; the outcome of the Company’s partnering/licensing efforts; risks associated with laws or regulatory requirements applicable to the Company, including the ability to come into compliance with The Nasdaq Capital Market listing requirements; market conditions; product performance; litigation or potential litigation; competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; manufacturing and supply chain risks; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2023, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this press release. Accordingly, you should not place undue reliance on the forward-looking statements made in this press release, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
FAQ
What will Plus Therapeutics (PSTV) present at the 2024 San Antonio Breast Cancer Symposium?
When is Plus Therapeutics (PSTV) presenting at the San Antonio Breast Cancer Symposium 2024?
What is the survival rate for leptomeningeal metastases that Plus Therapeutics (PSTV) is targeting?
